WRAIR-PAM-CF1

PreclinicalBiologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

WRAIR-PAM-CF1 is one of 44 biologic programs targeting Bacterial Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial DiseaseCompleted

Bacterial DiseasePreclinical

Completed

Competition

Competitive Landscape

43 competitors in Bacterial Disease

#DrugCompanyPhaseTrials

Zyvox

Dalvance

Ketek

Keflex

Doribax

Maxipime

Biaxin

Cipro

Aralen

Avelox

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Disease1 trial

A Phase 1b/2, Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Microbiological Activity of a Single Dose of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT05453578·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for WRAIR-PAM-CF1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WRAIR-PAM-CF1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WRAIR-PAM-CF1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

WRAIR-PAM-CF1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Disease1 trial

References

Drug Info

Quick Facts

Related News